FDA Advisory No.2022-1067 || Reminders regarding the conditions on the prescription and dispensation of oral COVID-19 Drugs under EUA with CMA
To allow greater access of the public, the Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) with Conditional Marketing Authorization (CMA) for Molnupiravir (several brand names) and […]
FDA Advisory No.2022-0938 || Guidelines on Receiving of Performance Testing Request at the Common Services Laboratory (CSL) – Physics Laboratory Support Division (PLSD)
The Food and Drug Administration (FDA) informs all concerned stakeholders and the general public that the Common Services Laboratory (CSL) – Physics Laboratory Support Division (PLSD) will implement the receiving […]
FDA Advisory No.2022-0931 || Food and Drug Administration (FDA) eServices Portal System Frequently Asked Questions (FAQs)
The Food and Drug Administration (FDA) is working to digitalize, simplify, and streamline its services through the establishment of online application platforms that are accessible for FDA stakeholders. Following this […]
FDA Advisory No.2022-0930 || APPLICATION PAYMENTS
In the interest of effective and efficient public service delivery, we would like to inform the general public that there are paid FDA applications remains unposted due to application case […]
FDA Advisory No.2022-0907 || Payment of Applications with Pre-Assessment
All are informed that payments made prior to the approval of the Pre-Assessment shall not be posted and shall not proceed on to the next process. With this, all are […]
FDA Advisory No.2022-0136 || List of VAT-Exempt Health Products pursuant to Republic Act No. 11534, otherwise known as the “Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act” and Frequently Asked Questions (FAQs)
For the information of all concerned, the List of Medicines for Hypertension, Cancer, Mental Illnesses, Tuberculosis, Kidney Diseases, Diabetes, and High Cholesterol, pursuant to the Implementing Guidelines on the Value-Added […]
FDA Advisory No.2022-0001-A || Amendment to FDA Advisory No. 2022-0001 Entitled “Food and Drug Action Center (FDAC) Services Beginning 10 January 2022”
In its commitment to provide effective and efficient releasing of authorizations to its clients, the Food and Drug Administration will re-open its Releasing Unit at the FDA main office located […]
FDA Advisory No.2022-0006 || UPDATED LIST OF DRUG PRODUCTS UNDER EMERGENCY USE (DEU) FOR COVID-19
Under FDA Circular 2021-008 or the Updated Guidelines for the Registration of Drug Products Under Emergency Use (DEU) for COVID-19, licensed drug establishments intending to manufacture and import/ distribute drug […]
FDA Advisory No.2022-0003 || New Office Address and Contact Numbers of the Food and Drug Action Center (FDAC)
Due to the recent fire incident in Starmall Alabang, the Food and Drug Action Center will temporarily be transferred and serve its clients in FDA Main Office. Please note of […]
FDA Advisory No.2022-0001 || FOOD AND DRUG ACTION CENTER (FDAC) SERVICES BEGINNING 10 JANUARY 2022
The Food and Drug Action Center (FDAC) is one of the several government offices at the Starmall Alabang which was heavily damaged and affected by the fire that broke out […]